Skip to main content
. 2018 Mar 16;118(8):1115–1122. doi: 10.1038/s41416-018-0038-5

Fig. 3.

Fig. 3

SLC3A2 and breast cancer patient outcome. a SLC3A2 vs BCSS in all cases, b SLC3A2 vs BCSS in all cases, c SLC3A2 vs BCSS of ER+ low-proliferation tumours, d SLC3A2 vs BCSS of ER+ high-proliferation tumours, e SLC3A2 vs BCSS in HER2+ tumours, f SLC3A2 vs BCSS in triple-negative tumours